Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 41, Issue 10, 1998, Pages 1714-1724

  Cooper, Glinda S ^a   Dooley, Mary Anne ^b   Treadwell, Edward L ^c   St Clair, E William ^d   Parks, Christine G ^b   Gilkeson, Gary S ^e  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d DUKE UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; FEMALE; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

BACTERIAL INFECTIONS; ENVIRONMENTAL EXPOSURE; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 0031695365     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U     Document Type: Review

References (99)

1. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330: 1871-9.
2. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-8.
3. Siegel M, Holley HL, Lee SL. Epidemiologic studies on systemic lupus erythematosus: comparative data for New York City and Jefferson County, Alabama, 1956-1965. Arthritis Rheum 1970;13: 802-11.
4. Fessel WJ. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974;134:1027-35.
5. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985;28:80-6.
6. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995;38:1260-70.
7. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8.
8. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. BrJ Rheumatol 1990;29:185-8.
9. Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol 1993;32:110-5.
10. Samanta A, Roy S, Feehally J, Symmons DPM. The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester City, UK. Br J Rheumatol 1992;31: 679-82.
11. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43.
12. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus-survival patterns: experience with 609 patients. JAMA 1981;245:934-8.
13. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
14. Symmons DPM. Frequency of lupus in people of African origin. Lupus 1995;4:176-8.
15. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences. Arch Intern Med 1990;150:849-53.
16. Molina JF, Molina J, García C, Gharavi AE, Wilson WA, Espinoza LR. Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans. Lupus 1997;6:63-7.
17. Dooley MA, Hogan S, Jennette C, Falk RJ, for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
18. Walsh SJ, Algert C, Gregorio DI, Reisine ST, Rothfield NF. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995;22:1663-8.
19. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25:601-11.
20. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
21. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
22. Ahmed SA, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases: mechanisms of sex hormone action. Am J Pathol 1985;121:531-51.
23. Lockshin MD. Why women? Lupus 1997;6:625-32.
24. Nelson JL. Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 1996;39:191-4.
25. Folomeev M, Dougados M, Beaune J, Kouyoumdjian J, Nahoul K, Amor B, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992;1:191-5.
26. Lahita RG, Bradlow L, Fishman J, Kunkel HG. Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum 1982;25:843-6.
27. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993;57:237-57.
28. White PC. Genetic diseases of steroid metabolism. Vitam Horm 1994;49:131-95.
29. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997; 18:207-14.
30. Nebert DW. Elevated estrogen 16α-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? J Natl Cancer Inst 1993;85:1888-91.
31. Parke AL, Parke DV, Jones FA. Diet and nutrition in rheumatoid arthritis and other chronic inflammatory diseases. J Clin Biochem Nutr 1996;20:1-26.
32. Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 1992; 19:1333-6.
33. Buskila D, Berezin M, Gur H, Lin HC, Alosachie I, Terryberry JW, et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun 1995;8:415-24.
34. Nagata C, Fujita S, Iwata H, Kurosawa Y, Kobayashi K, Kobayashi M, et al. Systemic lupus erythematosus: a case-control epidemiologic study in Japan. Int J Dermatol 1995;34:333-7.
35. Minami Y, Sasaki T, Komatsu S, Nishikori M, Fukao A, Yoshinaga K, et al. Female systemic lupus erythematosus in Miyagi prefecture, Japan: a case-control study of dietary and reproductive factors. Tohoku J Exp Med 1993;169:245-52.
36. Grimes DA, LeBolt SA, Grimes KR, Wingo PA. Systemic lupus erythematosus and reproductive function: a case-control study. Am J Obstet Gynecol 1985;153:179-86.
37. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women's health. Epidemiol Rev 1995;17:265-86.
38. Schachter M, Shoham Z. Amenorrhea during the reproductive years-is it safe? Fertil Steril 1994;62:1-16.
39. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
40. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
41. Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, Stolley PD. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 1994;140:632-42.
42. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40:804-8.
43. Annegers JF. Patterns of oral contraceptive use in the United States. Br J Rheumatol 1989;28 Suppl 1:48-50.
44. Moncayo R, Moncayo HE. The association of autoantibodies directed against ovarian antigens in human disease: a clinical review. J Intern Med 1993;234:371-8.
45. Ben-Chetrit A, Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum 1994; 37:1614-7.
46. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107-34.
47. Bigazzi PE. Autoimmunity and heavy metals. Lupus 1994;3:449-53.
48. Uetrecht JP. Mechanism of drug-induced lupus. Chem Res Toxicol 1988;1:133-43.
49. Silicosis and Silicate Disease Committee. Diseases associated with exposure to silica and nonfibrous silicate minerals. Arch Pathol Lab Med 1988;112:673-720.
50. Lippmann M, Eckert HL, Hahon N, Morgan WKC. Circulating antinuclear and rheumatoid factors in coal miners: a prevalence study in Pennsylvania and West Virginia. Ann Intern Med 1973; 79:807-11.
51. Calvert GM, Steenland K, Palu S. End-stage renal disease among silica-exposed gold miners: a new method for assessing incidence among epidemiologic cohorts. JAMA 1997;277:1219-23.
52. Sluis-Cremer GK, Hessel PA, Nizdo EH, Churchill AR, Zeiss EA. Silica, silicosis, and progressive systemic sclerosis. Br J Ind Med 1985;42:838-43.
53. Steenland K, Goldsmith DF. Silica exposure and autoimmune disease. Am J Ind Med 1995;28:603-8.
54. Steenland K, Brown D. Mortality study of gold miners exposed to silica and nonasbestiform amphibole minerals: an update with 14 more years of follow-up. Am J Ind Med 1995;27:217-29.
55. Brown LM, Gridley G, Olsen JH, Mellemkjær L, Linet MS, Fraumeni JF Jr. Cancer risk and mortality patterns among silicotic men in Sweden and Denmark. J Occup Environ Med 1997;39: 633-8.
56. Conrad K, Mehlhorn J, Lüthke K, Dörner T, Frank KH. Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 1996;5:62-9.
57. Sanchez-Roman J, Wichmann I, Salaberri J, Varela JM, Nuñez-Roldan A. Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 1993;52:534-8.
58. Nagata C, Yoshida H, Fujita S, Komura Y, Inaba R, Iwata H, et al. A case-control of SLE based on patients receiving financial aid for treatment. In: Yanagawa H, Sasaki R, Nagai M, Ohno Y, Hirohata T, Hashimoto T, et al, editors. Recent progress of epidemiologic study of intractable diseases in Japan. Tokyo: Ministry of Health and Welfare of Japan; 1992. p. 113-6.
59. Pernis B, Paronetto F. Adjuvant effects of silica (tridymite) on antibody production. Proc Soc Exp Biol Med 1962;110:390-2.
60. Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol 1982;10:303-19.
61. Driscoll KE, Lindenschmidt RC, Maurer JK, Higgins JM, Ridder G. Pulmonary response to silica or titanium dioxide: inflammatory cells, alveolar macrophage-derived cytokines, and histopathology. Am J Respir Cell Mol Biol 1990;2:381-90.
62. Ueki A, Yamaguchi M, Ueki H, Watanabe Y, Ohsawa G, Kinugawa K, et al. Polyclonal human T-cell activation by silicate in vitro. Immunology 1994;82:332-5.
63. Green FHY, Yoshida K, Fick G, Paul J, Hugh A, Green WF. Characterization of airborne mineral dusts associated with farming activities in rural Alberta, Canada. Int Arch Occup Environ Health 1990;62:423-30.
64. Stopford CM, Stopford W. Potential for respirable quartz exposure from North Carolina farm soils. Scand J Work Environ Health 1995;21 Suppl 2:44-6.
65. Freni-Titulaer LWJ, Kelley DB, Grow AG, McKinley TW, Arnett FC, Hochberg MC. Connective tissue disease in southeastern Georgia: a case-control study of etiologic factors. Am J Epidemiol 1989;130:404-9.
66. Petri M, Allbritton J. Hair product use in systemic lupus erythematosus: a case-control study. Arthritis Rheum 1992;35:625-9.
67. Reidenberg MM, Drayer DE, Lorenzo B, Strom BL, West SL, Snyder ES, et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 1993;36:971-3.
68. Sanchez-Guerrero J, Karlson EW, Colditz GA, Hunter DJ, Speizer FE, Liang MH. Hair dye use and the risk of developing systemic lupus erythematosus: a cohort study. Arthritis Rheum 1996;39:657-62.
69. Benoni C, Nilsson Å, Nived O. Smoking and inflammatory bowel disease: comparison with systemic lupus erythematosus: a case-control study. Scand J Gastroenterol 1990;25:751-5.
70. Kilburn KH, Warshaw RH. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res 1992;57:1-9.
71. Wallace DJ, Quismorio FP Jr. The elusive search for geographic clusters of systemic lupus erythematosus: critical review. Arthritis Rheum 1995;38:1564-7.
72. Khan MF, Kaphalia BS, Prabhakar BS, Kanz MR, Ansari GAS. Trichloroethene-induced autoimmune response in female MRL +/+ mice. Toxicol Appl Pharmacol 1995;134:155-60.
73. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996;15:273-80.
74. May DG. Genetic differences in drug disposition. J Clin Pharmacol 1994;34:881-97.
75. Safe SH, Zacharewski T. Organochlorine exposure and risk for breast cancer. Prog Clin Biol Res 1997;396:133-45.
76. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist. Nature 1995;375:581-5.
77. Vos JG, van Loveren H. Markers for immunotoxic effects in rodents and man. Toxicol Lett 1995;82-83:385-94.
78. Fan F, Pinson DM, Rozman KK. Immunomodulatory effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin tested by the popliteal lymph node assay. Toxicol Pathol 1995;23:513-7.
79. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996;25:318-36.
80. Gilkeson GS, Pippen AMM, Pisetsky DS. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 1995;95: 1398-402.
81. Hardgrave KL, Neas BR, Scofield RH, Harley JB. Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects. Arthritis Rheum 1993;36: 962-70.
82. Sabbatini A, Bombardieri S, Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol 1993;23:1146-52.
83. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
84. Rider JR, Ollier WER, Lock RJ, Brookes ST, Pamphilon DH. Human cytomegalovirus infection and systemic lupus erythematosus. Clin Exp Rheumatol 1997;15:405-9.
85. Talal N, Flescher E, Dang H. Are endogenous retroviruses involved in human autoimmune disease? J Autoimmun 1992;5 Suppl A:61-6.
86. Kalden JR, Gay S. Retroviruses and autoimmune rheumatic diseases. Clin Exp Immunol 1994;98:1-5.
87. gag antigen. Cell 1987;51:211-20.
88. Perl A, Colombo E, Dai H, Agarwal R, Mark KA, Banki K, et al. Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes: correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum 1995;38:1660-71.
89. Cope AP, Jones A, Brozovic M, Shafi MS, Maini RN. Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis 1992;51:803-4.
90. Granholm NA, Cavallo T. Autoimmunity, polyclonal B cell activation and infection. Lupus 1992;1:63-74.
91. Butcher GA. Malaria and macrophage function in Africans: a possible link with autoimmune disease? Med Hypotheses 1996;47: 97-100.
92. Weimann BJ, Weiser H. Effects of antioxidant vitamins C, E, and β-carotene on immune functions in MRL/lpr mice and rats. Ann N Y Acad Sci 1992;669:390-2.
93. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin Immunol Immunopathol 1994;72:193-7.
94. Comstock GW, Burke AE, Hoffman SC, Helzlsouer KJ, Bendich A, Masi AT, et al. Serum concentrations of α tocopherol, β carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1997;56:323-5.
95. Montanaro A, Bardana EJ Jr. Dietary amino acid-induced systemic lupus erythematosus. Rheum Dis Clin North Am 1991;17: 323-32.
96. McAlindon T, Felson D, Palmer J, Zhang Y, Rosenberg L. Associations of cigarette smoking and alcohol with systemic lupus erythematosus among participants in the Black Women's Health Study [abstract]. Arthritis Rheum 1997;40 Suppl 9:S162.
97. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
98. Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995;4:425-37.
99. Cavalli-Sforza LL, Piazza A. Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1993;1:3-18.